March 25, 2023

BREAKING NEWS

CLL Society’s COVID-19 Update for the Week of March 20, 2023

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

Support Groups | Researchers

Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Support Groups | Newsletter Sign Up | Donate Now

December 16, 2019

December 16, 2019

ASCO 2019: Dr. Koffman’s Pick #6: Acalabrutinib with Obinutuzumab for chronic lymphocytic leukemia (CLL)

Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society of Clinical Oncology Annual Meeting held May 31 – June 4, 2019, Chicago, IL. #6 Acalabrutinib with obinutuzumab

December 16, 2019

ASCO 2019: Dr. Koffman’s Pick #5 MRD Negative Responses after Liso-Cel or JCAR017 in chronic lymphocytic leukemia (CLL)

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

CLL SOCIETY FAST FIND

One click to our most popular content.

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL HEALTHCARE PROVIDERS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

QUICK LINKS

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL HEALTHCARE PROVIDERS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

December 16, 2019

ASCO 2019: Dr. Koffman’s Pick #6: Acalabrutinib with Obinutuzumab for chronic lymphocytic leukemia (CLL)

ASCO 2019: Dr. Koffman’s Pick #5 MRD Negative Responses after Liso-Cel or JCAR017 in chronic lymphocytic leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT